Goran Mićević, MD, PhD
Dermatology, Dermatopathology, Melanoma and Onco-Dermatology
Biography
Goran Micevic, MD, PhD, is a dermatologist specializing in dermatopathology, melanoma, and onco-dermatology. He focuses on diagnosing and treating skin cancers, including melanoma, and explores chronic inflammatory skin conditions such as atopic dermatitis, alopecia areata, and psoriasis.
As an assistant professor of dermatology at Yale School of Medicine, Dr. Micevic studies how the immune system affects skin diseases, including melanoma (a type of skin cancer) and other inflammatory skin conditions. His research looks at how immune cells cause skin inflammation in both cancer and non-cancer cases. He also studies changes in genes and gene activity to find better ways to predict outcomes and develop new treatments for melanoma.
Dr. Micevic earned his medical and doctoral degrees from Yale School of Medicine. Following his residency in dermatology and fellowship in dermatopathology at Yale New Haven Hospital, he undertook postdoctoral research in immunobiology.
Titles
- Assistant Professor
Education & Training
- MDYale School of Medicine (2018)
- PhDYale University (2016)
Additional Information
Honors & Recognitions
- Career Development Award: Dermatology Foundation (2023)
- Dermatologist Investigator Research Fellowship: Dermatology Foundation (2022)
- Ruth L. Kirschstein National Research Service Award: National Cancer Institute (2019)
- Selma & Karl Folkers Prize in Biomedical Research: Yale University (2018)
- Milton C. Winternitz Prize: Yale University (2018)
- John Epstein Scholar Award: (2017)
- Society for Melanoma Research Travel Award: Society for Melanoma Research (2016)
- American Skin Association Skin Cancer Grant: American Skin Association (2016)
- Paul and Daisy Soros Fellowship: (2016)
Board Certifications
- AB of Dermatology, Dermatopathology (2024)
- AB of Dermatology, Dermatology (2022)
Professional Service
- American Society for Investigative Pathology (2026 - 2027): The Program Committee plans the scientific program for the annual meeting and shall make recommendations to the Council for affiliations for future annual meetings. In addition, the Program Committee may plan additional scientific meetings with the approval of the Council.
- The British Journal of Dermatology (2024 - Present): Associate Editor for Translational Science
Publications
- Richmond R, Kidacki M, Micevic G. Misinformation is present in popular social media content about melanoma. Clinical And Experimental Dermatology 2026, llag181. PMID: 42033149, DOI: 10.1093/ced/llag181.
- Wang S, George D, Micevic G. Cutaneous Metastatic Carcinoma from Gastric Adenocarcinoma: Atypical Facial and Neck Eczematous Presentation. JAAD Case Reports 2026 DOI: 10.1016/j.jdcr.2026.03.032.
- Tan Y, Kim B, Mujal A, Chen A, Weis A, Bergaggio E, Micevic G, Xie H, Park J, Hor J, Papanicolaou M, Shobaki N, Domizi P, Delconte R, Vendramin R, Hegde S, Han S, Su Y, Hacohen N. Training Tomorrow's Leaders in Cancer Immunology. Cancer Immunology Research 2026, 14: 186-193. PMID: 41524276, DOI: 10.1158/2326-6066.cir-25-1479.
- Gehlhausen J, Luyten S, Deng J, Micevic G, Cohen J, Damsky W, Cowper S, McNiff J, Ko C. Leveraging Interpretable AI for Deciphering Signature Histopathologic Patterns. Journal Of Cutaneous Pathology 2026, 53: 370-376. PMID: 41479397, DOI: 10.1111/cup.70048.
- Talty R, Brooks V, McGeary M, Milette S, Zheng S, Flem-Karlsen K, Daniels A, Deshmukh M, Park K, Caraccio W, Yan H, Echeandia-Francis C, McNamara M, Hong S, Kirwin D, Olino K, Johnson C, Bosenberg M, Micevic G, Roy S. Lipophilic statins deplete GPX4 to promote ferroptosis and sensitize cancer cells to immune checkpoint blockade. Molecular Cancer Therapeutics 2025, 25: 759-770. PMID: 41423587, PMCID: PMC12752129, DOI: 10.1158/1535-7163.mct-25-0667.
- Odell A, Newton N, Eisenstein A, Micevic G, Flavell R, Odell I. EGFR-STAT1 pathway drives fibrosis initiation in fibroinflammatory skin diseases. Nature Communications 2025, 16: 8969. PMID: 41068129, PMCID: PMC12511620, DOI: 10.1038/s41467-025-64648-9.
- Flem-Karlsen K, Talty R, McGeary M, Park K, Thakral D, Brooks V, Daniels A, Damsky W, Roy S, Micevic G, Bosenberg M. Cytotoxic CD8+ T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity. Cancer Research 2025, 85: 4139-4150. PMID: 40828991, DOI: 10.1158/0008-5472.can-24-1952.
- Aung T, Liu M, Su D, Shafi S, Boyaci C, Steen S, Tsiknakis N, Vidal J, Maher N, Micevic G, Tan S, Vesely M, Nourmohammadi S, Bai Y, Djureinovic D, Wong P, Bates K, Chan N, Gavirelatou N, He M, Burela S, Barna R, Bosic M, Bräutigam K, Illabochaca I, Chenhao Z, Gama J, Kreis B, Mohacsi R, Pillar N, Pinto J, Poulios C, Toli M, Tzoras E, Bracero Y, Bosisio F, Cserni G, Dema A, Fortarezza F, Gonzalez M, Gullo I, Gutiérrez F, Hacihasanoglu E, Jovic V, Lazar B, Olinca M, Neppl C, Oliveira R, Pezzuto F, Pinto D, Plotar V, Pop O, Rau T, Skok K, Sun W, Serbes E, Solass W, Stanowska O, Szasz M, Szymonski K, Thimm F, Vignati D, Vigdorovits A, Prieto V, Sinnberg T, Wilmott J, Cowper S, Warrell J, Saenger Y, Hartman J, Plummer J, Osman I, Rimm D, Acs B. Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma. JAMA Network Open 2025, 8: e2518906. PMID: 40608341, PMCID: PMC12232186, DOI: 10.1001/jamanetworkopen.2025.18906.
- Deshmukh M, Brooks V, Roy S, Milette S, Bosenberg M, Micevic G. DNA methylation in melanoma immunotherapy: mechanisms and therapeutic opportunities. Clinical Epigenetics 2025, 17: 71. PMID: 40307913, PMCID: PMC12044936, DOI: 10.1186/s13148-025-01865-5.
- Qin T, Mattox A, Campbell J, Park J, Shin K, Li S, Sadow P, Faquin W, Micevic G, Daniels A, Haddad R, Garris C, Pittet M, Mempel T, ONeill A, Sartor M, Pai S. Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge. Journal Of Clinical Investigation 2025, 135: e181671. PMID: 40091844, PMCID: PMC11910227, DOI: 10.1172/jci181671.
- Sefik E, Xiao T, Chiorazzi M, Odell I, Zhang F, Agrawal K, Micevic G, Flavell R. Engineering Mice to Study Human Immunity. Annual Review Of Immunology 2025, 43: 451-487. PMID: 40020225, DOI: 10.1146/annurev-immunol-082523-124415.
- Balter D, Cao Y, Garritano J, Micevic G, Sanchez A. Non-uremic calciphylaxis: A dermatologic complication in both MASH and alcohol-associated cirrhosis. Clinical Nephrology - Case Studies 2025, 13: 8-12. PMID: 39949516, PMCID: PMC11823000, DOI: 10.5414/cncs111578.
- Aggarwal S, Andreani C, Deng Z, Frede J, Kameneva P, Kovatcheva M, Micevic G, Nicolson F, Puschhof J, Roberts M, Wang G, Watson D. The 2024 generation. Nature Cancer 2024, 5: 1774-1778. PMID: 39690227, DOI: 10.1038/s43018-024-00866-2.
- McGeary M, Damsky W, Daniels A, Lang S, Xu Q, Song E, Huet-Calderwood C, Lou H, Paradkar S, Micevic G, Kaech S, Calderwood D, Turk B, Yan Q, Iwasaki A, Bosenberg M. Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma. Cancer Immunology Research 2024, 13: 245-257. PMID: 39589394, DOI: 10.1158/2326-6066.cir-23-0514.
- Swallow M, Micevic G, Zhou A, Carlson K, Foss F, Girardi M. Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas. Cancers 2024, 16: 3087. PMID: 39272944, PMCID: PMC11394026, DOI: 10.3390/cancers16173087.
- Roy S, Baig J, DeCoste R, Finch S, Sennik S, Kakadekar A, Sade S, Micevic G, Chergui M, Rahimi K, Flaman A, Trinh V, Osmond A. Tumour necrosis is a valuable histopathological prognostic parameter in melanomas of the vulva and vagina. Pathology 2024, 56: 854-864. PMID: 38906758, DOI: 10.1016/j.pathol.2024.03.008.
- Talty R, Richmond R, Micevic G. Melanoma tumour-infiltrating T-lymphocyte therapy heralds the era of cell-based immunotherapies for solid tumours. British Journal Of Dermatology 2024, 190: 779-781. PMID: 38516835, DOI: 10.1093/bjd/ljae126.
- Roy S, Micevic G, McNiff J, Christensen S, Cowper S. Cutaneous diatoms from diatomaceous earth mimicking myiasis infection. Pathology 2024, 56: 742-743. PMID: 38471986, DOI: 10.1016/j.pathol.2023.12.416.
- Micevic G, Daniels A, Flavell R. New insights into programmed cell death protein 1 blockade-associated cutaneous immune-related adverse events. British Journal Of Dermatology 2023, 189: 355-357. PMID: 37471669, PMCID: PMC10503525, DOI: 10.1093/bjd/ljad236.
- Micevic G, Daniels A, Flem-Karlsen K, Park K, Talty R, McGeary M, Mirza H, Blackburn H, Sefik E, Cheung J, Hornick N, Aizenbud L, Joshi N, Kluger H, Iwasaki A, Bosenberg M, Flavell R. IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memory. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2304319120. PMID: 37459511, PMCID: PMC10372654, DOI: 10.1073/pnas.2304319120.
- Micevic G, Bosenberg M, Yan Q. The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy. Clinical Cancer Research 2022, 29: 1173-1182. PMID: 36449280, PMCID: PMC10073242, DOI: 10.1158/1078-0432.ccr-22-0784.
- Talty R, Micevic G, Damsky W, King BA. Erythrodermic scabies in an immunocompetent patient. JAAD Case Reports 2022, 29: 112-115. PMID: 36262356, PMCID: PMC9573821, DOI: 10.1016/j.jdcr.2022.08.045.
- Talty R, Micevic G, Wang A, Ko CJ, Damsky W. Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist. Case Reports In Dermatology 2022, 14: 214-218. PMID: 36158852, PMCID: PMC9459519, DOI: 10.1159/000525894.
- Micevic G, Lo SN, Rajan N. Targeting the neonatal Fc receptor in pemphigus: safety first. British Journal Of Dermatology 2021, 186: 389-390. PMID: 34961930, PMCID: PMC9295899, DOI: 10.1111/bjd.20939.
- Zhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, McGeary MK, Song E, Blenman KRM, Micevic G, Jessel S, Zhang Y, Yin M, Booth CJ, Jilaveanu LB, Damsky W, Sznol M, Kluger HM, Iwasaki A, Bosenberg MW, Yan Q. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. Nature 2021, 598: 682-687. PMID: 34671158, PMCID: PMC8555464, DOI: 10.1038/s41586-021-03994-2.
- Micevic G, Morris J, Lee AI, King BA. Perniolike lesions and coagulopathy in a patient with COVID-19 infection. JAAD Case Reports 2020, 6: 1294-1296. PMID: 32953959, PMCID: PMC7491482, DOI: 10.1016/j.jdcr.2020.08.042.
- Newton AS, Faver JC, Micevic G, Muthusamy V, Kudalkar SN, Bertoletti N, Anderson KS, Bosenberg MW, Jorgensen WL. Structure-Guided Identification of DNMT3B Inhibitors. ACS Medicinal Chemistry Letters 2020, 11: 971-976. PMID: 32435413, PMCID: PMC7236258, DOI: 10.1021/acsmedchemlett.0c00011.
- Vohhodina J, Toomire KJ, Petit SA, Micevic G, Kumari G, Botchkarev VV, Li Z, Livingston DM, Hu Y. RAP80 and BRCA1 PARsylation protect chromosome integrity by preventing retention of BRCA1-B/C complexes in DNA repair foci. Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 2084-2091. PMID: 31932421, PMCID: PMC6995001, DOI: 10.1073/pnas.1908003117.
- Micevic G, Thakral D, McGeary M, Bosenberg M. PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival. Pigment Cell & Melanoma Research 2018, 32: 435-440. PMID: 30343532, PMCID: PMC6475614, DOI: 10.1111/pcmr.12745.
- Theodosakis N, Langdon CG, Micevic G, Krykbaeva I, Means RE, Stern DF, Bosenberg MW. Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment‐resistant melanoma, colorectal, and lung cancer. Pigment Cell & Melanoma Research 2018, 32: 292-302. PMID: 30281931, PMCID: PMC6590911, DOI: 10.1111/pcmr.12742.
- Micevic G, Perkins SH, Zubek AE. Balanitis associated with FOLFIRI chemotherapy. JAAD Case Reports 2017, 4: 58-60. PMID: 29387750, PMCID: PMC5771729, DOI: 10.1016/j.jdcr.2017.09.001.
- Wang J, Perry CJ, Meeth K, Thakral D, Damsky W, Micevic G, Kaech S, Blenman K, Bosenberg M. UV‐induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model. Pigment Cell & Melanoma Research 2017, 30: 428-435. PMID: 28379630, PMCID: PMC5820096, DOI: 10.1111/pcmr.12591.
- Theodosakis N, Micevic G, Langdon CG, Ventura A, Means R, Stern DF, Bosenberg MW. p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis. Journal Of Investigative Dermatology 2017, 137: 2187-2196. PMID: 28599981, PMCID: PMC6342201, DOI: 10.1016/j.jid.2016.12.033.
- Micevic G, Theodosakis N, Bosenberg M. Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clinical Epigenetics 2017, 9: 34. PMID: 28396701, PMCID: PMC5381063, DOI: 10.1186/s13148-017-0332-8.
- Micevic G, Theodosakis N, Taube JM, Bosenberg MW, Rodi N. Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas. Melanoma Research 2017, 27: 85-96. PMID: 27997431, PMCID: PMC5812886, DOI: 10.1097/cmr.0000000000000315.
- Meeth K, Wang JX, Micevic G, Damsky W, Bosenberg MW. The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell & Melanoma Research 2016, 29: 590-597. PMID: 27287723, PMCID: PMC5331933, DOI: 10.1111/pcmr.12498.
- Brooks ED, Schoenhals JE, Tang C, Micevic G, Gomez DR, Chang JY, Welsh JW. Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. The Cancer Journal 2016, 22: 257-266. PMID: 27441745, PMCID: PMC5812885, DOI: 10.1097/ppo.0000000000000210.
- Criscione SW, Theodosakis N, Micevic G, Cornish TC, Burns KH, Neretti N, Rodić N. Genome-wide characterization of human L1 antisense promoter-driven transcripts. BMC Genomics 2016, 17: 463. PMID: 27301971, PMCID: PMC4908685, DOI: 10.1186/s12864-016-2800-5.
- Theodosakis N, Micevic G, Bosenberg MW, Rodić N. Cell and Tissue Display. Journal Of Histochemistry & Cytochemistry 2016, 64: 403-411. PMID: 27270967, PMCID: PMC4931762, DOI: 10.1369/0022155416651065.
- Theodosakis N, Micevic G, Sharma R, Baras AS, Lazova R, Bosenberg MW, Rodić N. Integrative discovery of CD98 as a melanoma biomarker. Pigment Cell & Melanoma Research 2016, 29: 385-387. PMID: 26850337, DOI: 10.1111/pcmr.12464.
- Chen F, Zhang Y, Şenbabaoğlu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, Xi L, Drummond JA, Muzny D, Kang H, Lee J, Tamboli P, Reuter V, Shelley CS, Kaipparettu BA, Bottaro DP, Godwin AK, Gibbs RA, Getz G, Kucherlapati R, Park PJ, Sander C, Henske EP, Zhou JH, Kwiatkowski DJ, Ho TH, Choueiri TK, Hsieh JJ, Akbani R, Mills GB, Hakimi AA, Wheeler DA, Creighton CJ. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Reports 2016, 14: 2476-2489. PMID: 26947078, PMCID: PMC4794376, DOI: 10.1016/j.celrep.2016.02.024.
- Micevic G, Muthusamy V, Damsky W, Theodosakis N, Liu X, Meeth K, Wingrove E, Santhanakrishnan M, Bosenberg M. DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR. Cell Reports 2016, 14: 2180-2192. PMID: 26923591, PMCID: PMC4785087, DOI: 10.1016/j.celrep.2016.02.010.
- Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, Tsui YC, Cui G, Micevic G, Perales JC, Kleinstein SH, Abel ED, Insogna KL, Feske S, Locasale JW, Bosenberg MW, Rathmell JC, Kaech SM. Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell 2015, 162: 1217-1228. PMID: 26321681, PMCID: PMC4567953, DOI: 10.1016/j.cell.2015.08.012.
- Theodosakis N, Held MA, Marzuka-Alcala A, Meeth KM, Micevic G, Long GV, Scolyer RA, Stern DF, Bosenberg MW. BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume. Molecular Cancer Therapeutics 2015, 14: 1680-1692. PMID: 25948295, PMCID: PMC4497841, DOI: 10.1158/1535-7163.mct-15-0080.
- Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M. mTORC1 Activation Blocks Braf V600E -Induced Growth Arrest but Is Insufficient for Melanoma Formation. Cancer Cell 2015, 27: 41-56. PMID: 25584893, PMCID: PMC4295062, DOI: 10.1016/j.ccell.2014.11.014.
- Theodosakis N, Micevic G, Kelly DP, Bosenberg M. Mitochondrial function in melanoma. Archives Of Biochemistry And Biophysics 2014, 563: 56-59. PMID: 24997363, DOI: 10.1016/j.abb.2014.06.028.
Departments and Programs
Biography
Goran Micevic, MD, PhD, is a dermatologist specializing in dermatopathology, melanoma, and onco-dermatology. He focuses on diagnosing and treating skin cancers, including melanoma, and explores chronic inflammatory skin conditions such as atopic dermatitis, alopecia areata, and psoriasis.
As an assistant professor of dermatology at Yale School of Medicine, Dr. Micevic studies how the immune system affects skin diseases, including melanoma (a type of skin cancer) and other inflammatory skin conditions. His research looks at how immune cells cause skin inflammation in both cancer and non-cancer cases. He also studies changes in genes and gene activity to find better ways to predict outcomes and develop new treatments for melanoma.
Dr. Micevic earned his medical and doctoral degrees from Yale School of Medicine. Following his residency in dermatology and fellowship in dermatopathology at Yale New Haven Hospital, he undertook postdoctoral research in immunobiology.
Titles
- Assistant Professor
Education & Training
- MDYale School of Medicine (2018)
- PhDYale University (2016)
Additional Information
Honors & Recognitions
- Career Development Award: Dermatology Foundation (2023)
- Dermatologist Investigator Research Fellowship: Dermatology Foundation (2022)
- Ruth L. Kirschstein National Research Service Award: National Cancer Institute (2019)
- Selma & Karl Folkers Prize in Biomedical Research: Yale University (2018)
- Milton C. Winternitz Prize: Yale University (2018)
- John Epstein Scholar Award: (2017)
- Society for Melanoma Research Travel Award: Society for Melanoma Research (2016)
- American Skin Association Skin Cancer Grant: American Skin Association (2016)
- Paul and Daisy Soros Fellowship: (2016)
Board Certifications
- AB of Dermatology, Dermatopathology (2024)
- AB of Dermatology, Dermatology (2022)
Professional Service
- American Society for Investigative Pathology (2026 - 2027): The Program Committee plans the scientific program for the annual meeting and shall make recommendations to the Council for affiliations for future annual meetings. In addition, the Program Committee may plan additional scientific meetings with the approval of the Council.
- The British Journal of Dermatology (2024 - Present): Associate Editor for Translational Science
Publications
- Richmond R, Kidacki M, Micevic G. Misinformation is present in popular social media content about melanoma. Clinical And Experimental Dermatology 2026, llag181. PMID: 42033149, DOI: 10.1093/ced/llag181.
- Wang S, George D, Micevic G. Cutaneous Metastatic Carcinoma from Gastric Adenocarcinoma: Atypical Facial and Neck Eczematous Presentation. JAAD Case Reports 2026 DOI: 10.1016/j.jdcr.2026.03.032.
- Tan Y, Kim B, Mujal A, Chen A, Weis A, Bergaggio E, Micevic G, Xie H, Park J, Hor J, Papanicolaou M, Shobaki N, Domizi P, Delconte R, Vendramin R, Hegde S, Han S, Su Y, Hacohen N. Training Tomorrow's Leaders in Cancer Immunology. Cancer Immunology Research 2026, 14: 186-193. PMID: 41524276, DOI: 10.1158/2326-6066.cir-25-1479.
- Gehlhausen J, Luyten S, Deng J, Micevic G, Cohen J, Damsky W, Cowper S, McNiff J, Ko C. Leveraging Interpretable AI for Deciphering Signature Histopathologic Patterns. Journal Of Cutaneous Pathology 2026, 53: 370-376. PMID: 41479397, DOI: 10.1111/cup.70048.
- Talty R, Brooks V, McGeary M, Milette S, Zheng S, Flem-Karlsen K, Daniels A, Deshmukh M, Park K, Caraccio W, Yan H, Echeandia-Francis C, McNamara M, Hong S, Kirwin D, Olino K, Johnson C, Bosenberg M, Micevic G, Roy S. Lipophilic statins deplete GPX4 to promote ferroptosis and sensitize cancer cells to immune checkpoint blockade. Molecular Cancer Therapeutics 2025, 25: 759-770. PMID: 41423587, PMCID: PMC12752129, DOI: 10.1158/1535-7163.mct-25-0667.
- Odell A, Newton N, Eisenstein A, Micevic G, Flavell R, Odell I. EGFR-STAT1 pathway drives fibrosis initiation in fibroinflammatory skin diseases. Nature Communications 2025, 16: 8969. PMID: 41068129, PMCID: PMC12511620, DOI: 10.1038/s41467-025-64648-9.
- Flem-Karlsen K, Talty R, McGeary M, Park K, Thakral D, Brooks V, Daniels A, Damsky W, Roy S, Micevic G, Bosenberg M. Cytotoxic CD8+ T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity. Cancer Research 2025, 85: 4139-4150. PMID: 40828991, DOI: 10.1158/0008-5472.can-24-1952.
- Aung T, Liu M, Su D, Shafi S, Boyaci C, Steen S, Tsiknakis N, Vidal J, Maher N, Micevic G, Tan S, Vesely M, Nourmohammadi S, Bai Y, Djureinovic D, Wong P, Bates K, Chan N, Gavirelatou N, He M, Burela S, Barna R, Bosic M, Bräutigam K, Illabochaca I, Chenhao Z, Gama J, Kreis B, Mohacsi R, Pillar N, Pinto J, Poulios C, Toli M, Tzoras E, Bracero Y, Bosisio F, Cserni G, Dema A, Fortarezza F, Gonzalez M, Gullo I, Gutiérrez F, Hacihasanoglu E, Jovic V, Lazar B, Olinca M, Neppl C, Oliveira R, Pezzuto F, Pinto D, Plotar V, Pop O, Rau T, Skok K, Sun W, Serbes E, Solass W, Stanowska O, Szasz M, Szymonski K, Thimm F, Vignati D, Vigdorovits A, Prieto V, Sinnberg T, Wilmott J, Cowper S, Warrell J, Saenger Y, Hartman J, Plummer J, Osman I, Rimm D, Acs B. Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma. JAMA Network Open 2025, 8: e2518906. PMID: 40608341, PMCID: PMC12232186, DOI: 10.1001/jamanetworkopen.2025.18906.
- Deshmukh M, Brooks V, Roy S, Milette S, Bosenberg M, Micevic G. DNA methylation in melanoma immunotherapy: mechanisms and therapeutic opportunities. Clinical Epigenetics 2025, 17: 71. PMID: 40307913, PMCID: PMC12044936, DOI: 10.1186/s13148-025-01865-5.
- Qin T, Mattox A, Campbell J, Park J, Shin K, Li S, Sadow P, Faquin W, Micevic G, Daniels A, Haddad R, Garris C, Pittet M, Mempel T, ONeill A, Sartor M, Pai S. Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge. Journal Of Clinical Investigation 2025, 135: e181671. PMID: 40091844, PMCID: PMC11910227, DOI: 10.1172/jci181671.
- Sefik E, Xiao T, Chiorazzi M, Odell I, Zhang F, Agrawal K, Micevic G, Flavell R. Engineering Mice to Study Human Immunity. Annual Review Of Immunology 2025, 43: 451-487. PMID: 40020225, DOI: 10.1146/annurev-immunol-082523-124415.
- Balter D, Cao Y, Garritano J, Micevic G, Sanchez A. Non-uremic calciphylaxis: A dermatologic complication in both MASH and alcohol-associated cirrhosis. Clinical Nephrology - Case Studies 2025, 13: 8-12. PMID: 39949516, PMCID: PMC11823000, DOI: 10.5414/cncs111578.
- Aggarwal S, Andreani C, Deng Z, Frede J, Kameneva P, Kovatcheva M, Micevic G, Nicolson F, Puschhof J, Roberts M, Wang G, Watson D. The 2024 generation. Nature Cancer 2024, 5: 1774-1778. PMID: 39690227, DOI: 10.1038/s43018-024-00866-2.
- McGeary M, Damsky W, Daniels A, Lang S, Xu Q, Song E, Huet-Calderwood C, Lou H, Paradkar S, Micevic G, Kaech S, Calderwood D, Turk B, Yan Q, Iwasaki A, Bosenberg M. Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma. Cancer Immunology Research 2024, 13: 245-257. PMID: 39589394, DOI: 10.1158/2326-6066.cir-23-0514.
- Swallow M, Micevic G, Zhou A, Carlson K, Foss F, Girardi M. Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas. Cancers 2024, 16: 3087. PMID: 39272944, PMCID: PMC11394026, DOI: 10.3390/cancers16173087.
- Roy S, Baig J, DeCoste R, Finch S, Sennik S, Kakadekar A, Sade S, Micevic G, Chergui M, Rahimi K, Flaman A, Trinh V, Osmond A. Tumour necrosis is a valuable histopathological prognostic parameter in melanomas of the vulva and vagina. Pathology 2024, 56: 854-864. PMID: 38906758, DOI: 10.1016/j.pathol.2024.03.008.
- Talty R, Richmond R, Micevic G. Melanoma tumour-infiltrating T-lymphocyte therapy heralds the era of cell-based immunotherapies for solid tumours. British Journal Of Dermatology 2024, 190: 779-781. PMID: 38516835, DOI: 10.1093/bjd/ljae126.
- Roy S, Micevic G, McNiff J, Christensen S, Cowper S. Cutaneous diatoms from diatomaceous earth mimicking myiasis infection. Pathology 2024, 56: 742-743. PMID: 38471986, DOI: 10.1016/j.pathol.2023.12.416.
- Micevic G, Daniels A, Flavell R. New insights into programmed cell death protein 1 blockade-associated cutaneous immune-related adverse events. British Journal Of Dermatology 2023, 189: 355-357. PMID: 37471669, PMCID: PMC10503525, DOI: 10.1093/bjd/ljad236.
- Micevic G, Daniels A, Flem-Karlsen K, Park K, Talty R, McGeary M, Mirza H, Blackburn H, Sefik E, Cheung J, Hornick N, Aizenbud L, Joshi N, Kluger H, Iwasaki A, Bosenberg M, Flavell R. IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memory. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2304319120. PMID: 37459511, PMCID: PMC10372654, DOI: 10.1073/pnas.2304319120.
- Micevic G, Bosenberg M, Yan Q. The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy. Clinical Cancer Research 2022, 29: 1173-1182. PMID: 36449280, PMCID: PMC10073242, DOI: 10.1158/1078-0432.ccr-22-0784.
- Talty R, Micevic G, Damsky W, King BA. Erythrodermic scabies in an immunocompetent patient. JAAD Case Reports 2022, 29: 112-115. PMID: 36262356, PMCID: PMC9573821, DOI: 10.1016/j.jdcr.2022.08.045.
- Talty R, Micevic G, Wang A, Ko CJ, Damsky W. Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist. Case Reports In Dermatology 2022, 14: 214-218. PMID: 36158852, PMCID: PMC9459519, DOI: 10.1159/000525894.
- Micevic G, Lo SN, Rajan N. Targeting the neonatal Fc receptor in pemphigus: safety first. British Journal Of Dermatology 2021, 186: 389-390. PMID: 34961930, PMCID: PMC9295899, DOI: 10.1111/bjd.20939.
- Zhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, McGeary MK, Song E, Blenman KRM, Micevic G, Jessel S, Zhang Y, Yin M, Booth CJ, Jilaveanu LB, Damsky W, Sznol M, Kluger HM, Iwasaki A, Bosenberg MW, Yan Q. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. Nature 2021, 598: 682-687. PMID: 34671158, PMCID: PMC8555464, DOI: 10.1038/s41586-021-03994-2.
- Micevic G, Morris J, Lee AI, King BA. Perniolike lesions and coagulopathy in a patient with COVID-19 infection. JAAD Case Reports 2020, 6: 1294-1296. PMID: 32953959, PMCID: PMC7491482, DOI: 10.1016/j.jdcr.2020.08.042.
- Newton AS, Faver JC, Micevic G, Muthusamy V, Kudalkar SN, Bertoletti N, Anderson KS, Bosenberg MW, Jorgensen WL. Structure-Guided Identification of DNMT3B Inhibitors. ACS Medicinal Chemistry Letters 2020, 11: 971-976. PMID: 32435413, PMCID: PMC7236258, DOI: 10.1021/acsmedchemlett.0c00011.
- Vohhodina J, Toomire KJ, Petit SA, Micevic G, Kumari G, Botchkarev VV, Li Z, Livingston DM, Hu Y. RAP80 and BRCA1 PARsylation protect chromosome integrity by preventing retention of BRCA1-B/C complexes in DNA repair foci. Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 2084-2091. PMID: 31932421, PMCID: PMC6995001, DOI: 10.1073/pnas.1908003117.
- Micevic G, Thakral D, McGeary M, Bosenberg M. PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival. Pigment Cell & Melanoma Research 2018, 32: 435-440. PMID: 30343532, PMCID: PMC6475614, DOI: 10.1111/pcmr.12745.
- Theodosakis N, Langdon CG, Micevic G, Krykbaeva I, Means RE, Stern DF, Bosenberg MW. Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment‐resistant melanoma, colorectal, and lung cancer. Pigment Cell & Melanoma Research 2018, 32: 292-302. PMID: 30281931, PMCID: PMC6590911, DOI: 10.1111/pcmr.12742.
- Micevic G, Perkins SH, Zubek AE. Balanitis associated with FOLFIRI chemotherapy. JAAD Case Reports 2017, 4: 58-60. PMID: 29387750, PMCID: PMC5771729, DOI: 10.1016/j.jdcr.2017.09.001.
- Wang J, Perry CJ, Meeth K, Thakral D, Damsky W, Micevic G, Kaech S, Blenman K, Bosenberg M. UV‐induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model. Pigment Cell & Melanoma Research 2017, 30: 428-435. PMID: 28379630, PMCID: PMC5820096, DOI: 10.1111/pcmr.12591.
- Theodosakis N, Micevic G, Langdon CG, Ventura A, Means R, Stern DF, Bosenberg MW. p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis. Journal Of Investigative Dermatology 2017, 137: 2187-2196. PMID: 28599981, PMCID: PMC6342201, DOI: 10.1016/j.jid.2016.12.033.
- Micevic G, Theodosakis N, Bosenberg M. Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clinical Epigenetics 2017, 9: 34. PMID: 28396701, PMCID: PMC5381063, DOI: 10.1186/s13148-017-0332-8.
- Micevic G, Theodosakis N, Taube JM, Bosenberg MW, Rodi N. Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas. Melanoma Research 2017, 27: 85-96. PMID: 27997431, PMCID: PMC5812886, DOI: 10.1097/cmr.0000000000000315.
- Meeth K, Wang JX, Micevic G, Damsky W, Bosenberg MW. The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell & Melanoma Research 2016, 29: 590-597. PMID: 27287723, PMCID: PMC5331933, DOI: 10.1111/pcmr.12498.
- Brooks ED, Schoenhals JE, Tang C, Micevic G, Gomez DR, Chang JY, Welsh JW. Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. The Cancer Journal 2016, 22: 257-266. PMID: 27441745, PMCID: PMC5812885, DOI: 10.1097/ppo.0000000000000210.
- Criscione SW, Theodosakis N, Micevic G, Cornish TC, Burns KH, Neretti N, Rodić N. Genome-wide characterization of human L1 antisense promoter-driven transcripts. BMC Genomics 2016, 17: 463. PMID: 27301971, PMCID: PMC4908685, DOI: 10.1186/s12864-016-2800-5.
- Theodosakis N, Micevic G, Bosenberg MW, Rodić N. Cell and Tissue Display. Journal Of Histochemistry & Cytochemistry 2016, 64: 403-411. PMID: 27270967, PMCID: PMC4931762, DOI: 10.1369/0022155416651065.
- Theodosakis N, Micevic G, Sharma R, Baras AS, Lazova R, Bosenberg MW, Rodić N. Integrative discovery of CD98 as a melanoma biomarker. Pigment Cell & Melanoma Research 2016, 29: 385-387. PMID: 26850337, DOI: 10.1111/pcmr.12464.
- Chen F, Zhang Y, Şenbabaoğlu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, Xi L, Drummond JA, Muzny D, Kang H, Lee J, Tamboli P, Reuter V, Shelley CS, Kaipparettu BA, Bottaro DP, Godwin AK, Gibbs RA, Getz G, Kucherlapati R, Park PJ, Sander C, Henske EP, Zhou JH, Kwiatkowski DJ, Ho TH, Choueiri TK, Hsieh JJ, Akbani R, Mills GB, Hakimi AA, Wheeler DA, Creighton CJ. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Reports 2016, 14: 2476-2489. PMID: 26947078, PMCID: PMC4794376, DOI: 10.1016/j.celrep.2016.02.024.
- Micevic G, Muthusamy V, Damsky W, Theodosakis N, Liu X, Meeth K, Wingrove E, Santhanakrishnan M, Bosenberg M. DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR. Cell Reports 2016, 14: 2180-2192. PMID: 26923591, PMCID: PMC4785087, DOI: 10.1016/j.celrep.2016.02.010.
- Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, Tsui YC, Cui G, Micevic G, Perales JC, Kleinstein SH, Abel ED, Insogna KL, Feske S, Locasale JW, Bosenberg MW, Rathmell JC, Kaech SM. Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell 2015, 162: 1217-1228. PMID: 26321681, PMCID: PMC4567953, DOI: 10.1016/j.cell.2015.08.012.
- Theodosakis N, Held MA, Marzuka-Alcala A, Meeth KM, Micevic G, Long GV, Scolyer RA, Stern DF, Bosenberg MW. BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume. Molecular Cancer Therapeutics 2015, 14: 1680-1692. PMID: 25948295, PMCID: PMC4497841, DOI: 10.1158/1535-7163.mct-15-0080.
- Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M. mTORC1 Activation Blocks Braf V600E -Induced Growth Arrest but Is Insufficient for Melanoma Formation. Cancer Cell 2015, 27: 41-56. PMID: 25584893, PMCID: PMC4295062, DOI: 10.1016/j.ccell.2014.11.014.
- Theodosakis N, Micevic G, Kelly DP, Bosenberg M. Mitochondrial function in melanoma. Archives Of Biochemistry And Biophysics 2014, 563: 56-59. PMID: 24997363, DOI: 10.1016/j.abb.2014.06.028.
Departments and Programs